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Increasing evidence points to an important role for
the ribosome in the regulation of biological pro-
cesses and as a target for deregulation in disease.
Here, we describe a SILAC (stable isotope labeling
by amino acids in cell culture)-based mass spec-
trometry approach to probing mammalian ribopro-
teomes. Using a panel of cell lines, as well as genetic
and pharmacological perturbations, we obtained a
comparative characterization of the cellular ribopro-
teome. This analysis identified a set of riboproteome
components, consisting of a diverse array of proteins
with a strong enrichment for RNA-binding proteins.
Importantly, this global analysis uncovers a high inci-
dence of genetic alterations to riboproteome compo-
nents in cancer, with a distinct bias toward genetic
amplification. We further validated association with
polyribosomes for several riboproteome compo-
nents and demonstrate that enrichment at the ribo-
proteome can depend on cell type, genetics, or
cellular stimulus. Our results have important implica-
tions for the understanding of how ribosomes func-
tion and provide a platform for uncovering regulators
of translation.INTRODUCTION
For many years now, gene expression has been measured as a
reflection of transcriptional activation, and the assumption has
been made that the absolute level of mRNA for a given gene
within the cell directly correlates with protein level for that
gene. Although mRNA level strongly correlates with protein
expression, more recent evidence highlights the very important
role that posttranscriptional events, including translation and1276 Cell Reports 4, 1276–1287, September 26, 2013 ª2013 The AumicroRNA (miRNA) regulation of mRNA, play in regulating gene
expression (Xue and Barna, 2012; Fabian and Sonenberg,
2012). Similar to key regulators of gene transcription (e.g., p53
or c-Myc), key regulators of translation are specifically targeted
in human diseases, including cancer. Indeed, recent data sug-
gest that RNA binding proteins (RBPs) are frequently associated
with disease. For example, Fragile-X mental retardation protein
is involved in Fragile-X syndrome and autism (Darnell et al.,
2011), proteins such as musashi-1 and -2 are involved in stem
cell biology and leukemia (Kharas et al., 2010), and the NPM1
gene is frequently translocated and mutated in a variety of
hematological malignancies (Grisendi et al., 2006). Additionally,
deficiency and mutation of ribosome and ribosome biogenesis
proteins themselves are associated with disease and develop-
mental abnormalities, including Diamond-Blackfan anemia,
Shwachman-Diamond syndrome, and X-linked dyskeratosis
congenita (Narla and Ebert, 2010). However, a more global
approach to systematically determine in greater detail the
players that coordinate translation is currently lacking. Such an
approach will, in turn, enable the identification of key regulators
of translation in specific conditions and help better elucidate the
role that these proteins play in disease pathology.
The majority of actively translating ribosomes exist in the cell
as polysomes, multiple ribosomes loaded on mRNAs to direct
translation. However, the process of priming RNA for translation,
subsequent loading of ribosomes, and efficient translation
require a significant number of extraribosomal factors including
initiation/elongation factors and RNA helices that are critical to
efficient translation (Jackson et al., 2010). Thus, it is likely that
many players required for correct translation remain to be uncov-
ered, and this represents amajor bottleneck to understanding, in
depth, exactly how translation is coordinated.
Here, we applied a SILAC (stable isotope labeling by amino
acids in cell culture)-based mass spectrometry approach to
comprehensively characterize the proteins that constitute the
actively translating ribosome, i.e., the riboproteome, as defined
(1) by the proteins associated with the ribosome itself, and which
may be required for either directing translation or quality controlthors
of nascent proteins, and (2) by the proteins associated with
mRNAs undergoing active translation.
By employing this high-throughput approach to the analysis of
proteins associated with actively translating polysomes in
various cellular populations and under varying conditions, we
were able to obtain a comprehensive overview of the ribopro-
teome. We demonstrate the power of this approach to identify
differential riboproteome components among cancer cell lines
and in the analysis of genetic and pharmacological perturbations
to the riboproteome. This has allowed us to present a detailed
characterization of the prostate riboproteome and to highlight
the diversity of proteins that are associated with actively trans-
lating polysomes. Our data identify a number of components of
the riboproteome and demonstrate the ability of this approach
to address the dynamic nature of the riboproteome upon specific
perturbations. Furthermore, this platform will enable us to gain
important insights to the makeup of the riboproteome and will
help identify important factors associated with translational
regulation.
RESULTS
High-Throughput Analysis of the Riboproteome Using a
SILAC-Based Approach
We hypothesize that the process of active translation within the
cell is regulated by a multitude of proteins that can interact with
either the ribosome itself, the mRNAs that are being actively
translated, or proteins that may have the capacity to interact
with both the ribosome and mRNA.
In order to characterize the components that constitute the
actively translating ribosome (i.e., the riboproteome), we applied
a mass spectrometry approach to quantitatively evaluate
the protein components that are differentially associated with
translation in different cellular contexts, while also allowing for
a comprehensive overview of the proteins that make up the
riboproteome.
To this end, we cultured relevant cell lines of both mouse (e.g.,
mouse embryonic fibroblasts [MEFs]) and human origin (e.g.,
prostate cancer cell lines) with SILAC media to incorporate
amino acids for light (Lys0
C13; Arg0
N14) or heavy (Lys6
C13;
Arg10
N15) labeling of proteins, achieving a labeling efficiency of
greater than 95% (Table S1), and proceeded to isolate ribopro-
teome components as outlined in Figure 1A. Labeled cells
were seeded to ensure subconfluency at harvesting and were
treated with 100 mg/ml cycloheximide prior to harvesting (see
Experimental Procedures). Cells were collected in PBS contain-
ing cycloheximide, and equal amounts of cell lysates were
loaded on 15%–50% sucrose gradients. Polysomes were sepa-
rated by density gradient centrifugation and collected by frac-
tionation (Figure S1A). Protein from individual polysome fractions
was precipitated by deoxycholate-TCA precipitation and resus-
pended in buffer (0.1 M Tris [pH 8.8]; 1% SDS). Precipitated
protein from fractions containing polysomes for heavy and
light-labeled cells were combined in a ratio of 1:1 (v/v) and run
on an SDS-PAGE gel, which was subsequently stained using
Coomassie brilliant blue. The gel lane was cut into eight separate
pieces and submitted to the BIDMCMass Spectrometry Core for
analysis by microcapillary liquid chromatography-tandem massCell Respectrometry (LC-MS/MS) analysis on a hybrid linear ion trap-
orbitrap mass spectrometer. All resulting MS data were further
processed with Mascot or Andromeda and the MaxQuant soft-
ware suite as previously described (Cox and Mann, 2008; Cox
et al., 2011).
This whole procedure required considerable optimization, as
preliminary experiments identified extensive protease activity
in polysomal fractions, resulting in degradation to ribosomal
components and affecting quality of mass spectrometry results
(Figure S1B). In order to resolve these issues, we employed a
comprehensive array of protease inhibitors (as detailed in Exper-
imental Procedures), which completely eliminated such protease
activity and degradation artifacts.
To uncover the riboproteomic diversity within cellular popula-
tions, we applied this approach to a number of cell systems that
included both relevant human prostate cell lines (Du145, PC3,
PPC1 prostate cancer cell lines, and the immortalized prostatic
epithelial cell lines PWR1E and RWPE1) andMEFs (immortalized
Npm1 wild-type and null) as outlined in Figures 1A and S1C.
Initially, we compared actively translating polysomes from the
normal prostatic epithelial cell lines PWR1E and RWPE1 (two
immortalized cell lines routinely used as normal controls for
prostate cancer studies) with the metastatic prostate cancer
cell line Du145 (Figure S1C). Second, we compared the ribopro-
teomes of the prostate cancer cell lines Du145 and PC3. The use
of these four cell lines allowed us to evaluate how the ribopro-
teome changes from a relatively normal situation (PWRE1,
RWPE1) to a cancerous state (Du145) and between two different
cancer cell lines that harbor distinct genetic alterations (Du145
PTENwt;TP53mut and PC3 PTENnull;TP53null) (Figure S1C). Third,
we compared the riboproteomes of PPC1 prostate cancer cells
(PTENnull;TP53null) treated with the mTOR inhibitors rapamycin
and PP242 (Figure S1C). Finally, we compared MEFs harboring
wild-type or null alleles for the ribosome biogenesis gene
Npm1 (Figure S1C).
These data allowed us to determine the overall composition of
the ribosome and its associated proteins and evaluate quantita-
tive differences in components of the mammalian riboproteome.
Importantly, an initial comparison between polysomes derived
from Du145 heavy- and light-labeled cells revealed that all quan-
tified proteins showed an average Log2 (H/L) ratio of around
0 (226 quantified proteins; mean 0.0029, SD ±0.1866) (Figure 1B;
Table S2), demonstrating that differences observed between cell
lines do not arise from variations in sample preparation and con-
firming both reliability as well as reproducibility of the technique.
In further support of this approach as a method to study
composition and quantitative differences among riboproteomes,
a comparison of the two normal and cancer cell line (hereafter
referred to as N/C) data sets revealed a substantial overlap
in identified proteins from immortalized normal epithelial cell
lines, with a significant positive correlation (R2 = 0.4662, p = <
0.0001). This demonstrates that these normal cell lines share
significant similarity, which, in turn, gives greater significance
to differences that exist between normal and cancer ribopro-
teomes (Figure 1C).
Importantly, we detected several differences between the ri-
boproteomes of N/C data sets as well as between cancer cell
types (hereafter referred to as C/C) using indicated cutoff valuesports 4, 1276–1287, September 26, 2013 ª2013 The Authors 1277
Figure 1. A Quantitative Riboproteomics Approach to Study the Composition of Riboproteomes
(A) Schematic representation of the SILAC-based mass spectrometry experiments.
(B) Scatterplot with normalized Log2 (H/L) ratios/Log10 intensities highlighting the distribution of all quantified proteins between Du145 H- and L-labeled cells.
Note that most of the proteins have a ratio of 1:1 between the light and heavy state and therefore have a value close to 0 on a Log2 axis (mean 0.0229; SD 0.1866).
(C) Standard scatterplot with normalized Log2 (H/L) ratios comparing the twoN/C data sets (RWPE1 versus Du145 and PWR1E versus Du145). All shared proteins
between the data sets are plotted. Both data sets show a highly significant positive correlation (R2 = 0.4662; p = < 0.0001).
(D–F) Standard scatterplots with normalized Log2 (H/L) ratios/Log10 Intensities (Normal versus Cancer n = 3, left panel; Cancer versus Cancer n = 3, middle panel;
PPC1DMSO versus PP242, n = 3, right panel) highlighting the distribution of quantified proteins in each screen (cutoff values for enriched proteins was 2 SDs (2s)
from the mean, dashed red lines). Proteins of interest in either experimental setting are highlighted.
See also Figure S1 and Tables S1, S2, S3, S4, S5, S6, S7, S8, and S9.
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(cutoffs are based on two SDs from the mean) (Figures 1D, 1E,
and S1D). These differences are described in greater detail
below and include a variety of proteins including RBPs (e.g.,
IGF2BP2, IGF2BP3), cell adhesion molecules (e.g., Integrin b1),
and signaling proteins (e.g., MARCKS) among others.
In addition, acute exposure to the mTOR inhibitors rapamycin
and PP242 in PPC1 cells reveals that only strong inhibition of the
mTOR kinase itself results in a clear perturbation to the ribo-
proteome (Figures 1F and S1E). This is consistent with the differ-
ential capacity of these drugs to inhibit mTOR activity toward
translation (DMSO < rapamycin < PP242) with numerous ribo-
somal proteins and RBPs (e.g., RpL4, RpL6, RpS6, LARP pro-
teins), demonstrating the most striking quantitative differences
(Figures 1F and S1E).
Comparing Npm1 wild-type or null immortalized MEFs, we
combined mass spectrometry data from two separate biological
replicates, including a label switch. No change in relative quan-
tification of ribosomal proteins was observed between Npm1
wild-type and null immortalized MEFs (Figure S1F). Interestingly,
Npm1 was identified as the most highly decreased protein in
Npm1-null riboproteomes (Figure S1F), due to the presence of
N-terminal peptides that remain as a result of the knockout
strategy (Grisendi et al., 2005), thereby serving as an internal
positive control.
Notably, our approach identified and quantified all but one
(RpL41, a lysine- and arginine-rich 25 amino acid protein that
is unlikely to be identified by this mass spectrometry approach
due to the large number of sites available for trypsin cleavage,
and the consequent inability to generate multiple peptides) ribo-
somal protein (Figure S1G), as well as other known translation-
associated proteins including initiation and elongation factors
(see Tables S3, S4, S5, S6, S7, and S8). We observed that ribo-
somal proteins of both the small and the large subunit cluster
around a normalized Log2 (H/L) = 0 (Figure S1H), indicating
that ribosomal proteins are unchanged between normal and
cancer cells, as well as between cancer cell lines and genetically
definedMEFs. These data make the important point that, at least
among these cell lines, core ribosomal protein composition in
polysomes is not altered.
Characterization of the Riboproteome
Overall, the number of proteins quantified in each of the individ-
ual groups of experiments varied from 575 to 991 (Figure S2A)
and offered the potential to uncover a significant overlap of pro-
teins that makes up the riboproteomic space inmammalian cells.
To first examine how the data sets compared to one another,
we carried out an unsupervised hierarchical clustering of the six
conditions analyzed (Figure S2B). Interestingly, theMEF data set
appeared to cluster independently from the human prostate
cancer cells, whereas, among the prostate cancer cells, PPC1
cell lines cluster together and the immortalized prostate epithe-
lial cell lines cluster together. The PC3 and Du145 experiments
displayed greater similarity to immortalized epithelial cells, likely
due to their shared comparison. These data indicate that the
riboproteome itself may have the capacity to categorize cell
types and tissues based on riboproteomic diversity, and, in
turn, can contribute to regulation of gene expression within a
given cellular compartment.Cell ReIn addition to a number of significant differences identified
between the various samples, the hierarchical clustering clearly
demonstrated all prostate cell lines shared high similarity. Thus,
we chose to combine these data sets in order to gain a global
perspective of the prostate riboproteome. In the combined pros-
tate cell line data set, we identified a total of 1,499 quantified pro-
teins (Figure 2A; Table S9). Of these 1,499 proteins, 70% were
identified in at least two experimental data sets, whereas 24%
(363 of 1,499) were identified in all five experiments (Figure 2B;
Table S9). Indeed, this number of 363 core riboproteomic com-
ponents represents over 60% of the PC3/Du145 SILAC experi-
ment, which contained the lowest number of proteins identified
in the prostate cell line cohort (Figure S2A). It is also interesting
to note that 96% of proteins quantified in this PC3/Du145 data
set were found in at least one other data set, with only 21 proteins
quantified unique to this experiment (Figure S2; Table S9). These
data show strong overlap in proteins identified among the inde-
pendent riboproteome experiments and highlight the advantage
of using multiple cell lines to characterize the riboproteome.
We subsequently carried out Ingenuity Pathway Analysis
(http://www.ingenuity.com/) of all 1,499 proteins identified to
examine what (1) biological functions and (2) canonical pathways
may be specifically enriched in our data set. Importantly, we
found biological functions related to protein synthesis, post-
translational modification, and protein folding to be highly en-
riched in our combined data set (Figure S2D). In agreement
with this, the canonical pathway analysis demonstrated EIF2
signaling, regulation of eIF4 and p70S6K signaling, and mTOR
signaling pathways to be significantly represented (Figure S2E).
In addition, KEGG pathway analysis of proteins identified in all
five experimental data sets (363/1,499) compared to proteins
identified in at least one experiment (1,499) identified ribosome
related pathways to be highly enriched (Figure S2F).
Diversity of Protein Functional Groups and Enrichment
of RNA Binding Proteins in the Riboproteome
To better understand the various protein components that make
up the riboproteome, we used DAVID (david.abcc.ncifcrf.gov)
(Huang et al., 2009) to perform a gene ontology-based functional
categorization of the proteins identified in our combined data set
(Figure 2C). This analysis demonstrated a clear and significant
enrichment in ribosome and translation related processes. In
addition, a number of other diverse protein functional groups
were found to be included in the riboproteome, includingmelano-
some and glucose catabolic processes. Critically, we identified
a significant enrichment of RBPs to be constituents of the
riboproteome. As two recent papers published now describe
the RNA-binding protein interactome in detail (Baltz et al.,
2012; Castello et al., 2012), we compared riboproteome and
RBP-interactome data sets to evaluate the proportion of RBPs
that form part of the riboproteome. Using the data set from Cas-
tello et al. (2012), we find a considerable overlap between the
RBP interactome and riboproteome (Figure 2D). Strikingly, core
riboproteome components show themselves to be enriched in
RBP-interactome proteins (50% of proteins identified can be as-
signed to the RBP interactome, Figure 2E, left panel), whereas
those proteins identified in only one experimental condition
have a much lower RBP-interactome component (only 29% ofports 4, 1276–1287, September 26, 2013 ª2013 The Authors 1279
(legend on next page)
1280 Cell Reports 4, 1276–1287, September 26, 2013 ª2013 The Authors
proteins identified can be assigned to the RBP interactome, Fig-
ure S2H, left panel). Moreover, it is interesting to note that, when
we break down our riboproteome RBPs according to the cate-
gories defined by Castello et al. (2012) in Figure S2G (i.e.,
mRNA-interactome; candidate RBP; no evidence), we find that
their proportional distribution in these three categories is highly
similar to those described by Castello et al. (2012) (Figures 2E
andS2H, right panels for RBPcategories from the riboproteome).
Riboproteomic Genes Are Frequently Amplified in
Human Cancer
As cellular proliferation is strongly coupled to translation, we next
evaluated if the riboproteome may be altered in human cancer
using the cBio Cancer Genomics Portal (http://cbioportal.org)
and the R package cgdsr, developed at Memorial Sloan-Ketter-
ing Cancer Center.
We first examined the distribution of copy-number alterations
in the riboproteome as compared with genes in the background
genome across 16 cancer types. This analysis included between
1,661 and 1,720 of the riboproteome genes (median = 1,675)
and 19,195 nonriboproteome background genes. The overall
analysis shows that the riboproteome is enriched for copy-num-
ber gains and high-level amplifications (Figures 3A and S3A) and
depleted for hemizygous and homozygous deletions (all p <
2.2e16) (Figures 3B and S3B).
Based on these data, we sought to identify riboproteomic
genes that undergo the most frequent copy-number alterations
in specific cancer types. This analysis focused on 532 ribopro-
teome genes with complete copy-number data across 15 cancer
types. Riboproteome genes were ranked by the maximum num-
ber of cases where they showed a genomic amplification across
the 15 cancers (Figures 3C and S3C). Interestingly, we observed
that 38 riboproteome genes correlated with high-level amplifica-
tions in at least 10% of at least one cancer type (Figure 3D).
Although several genetic loci are represented in this data set
including 4p16.3, 1p33, and 19p13, more than half of these
genes (60%, 23 of 38) grouped to three specific genetic loci.
These loci represented 1q22, 3q26, and 8q24, with regions sur-
rounding chromosome 3q26 and 8q24 identified as showing
most frequent amplification (Figures 3C and 3D). Analysis of
the gene signature for the 3q riboproteomic gene locus (nine
genes) in the TCGA studies containing mutation data showed
that 51% (91 of 178 cases) of lung squamous cell carcinoma
contained an alteration in at least one of these genes (Figure 3E,Figure 2. Analysis of the Prostate Riboproteome
(A) Venn diagram showing how proteins identified in each of the five SILAC experim
sets. Out of total of 1,499 proteins quantified between all experiments, 363 are s
(B) Pie chart illustrating the distribution of proteins identified across the various exp
detached blue pie slice, whereas proteins identified in all five experiments (24%
(C) Gene ontology (GO) analysis of the prostate riboproteome highlights multiple
riboproteome. A table of significantly enriched GO terms relating to translation id
(D) Venn diagram indicating the extent of overlap between the RNA binding prote
constituents described here.
(E) Pie charts to illustrate the extent to which components of the RBP interactome o
proteins that are also called within the Castello et al. (2012) data set for the co
illustrates how the RBP-interactome components identified in the riboproteomic d
by Castello et al. (2012).
See also Figure S2.
Cell Releft panel). Ovarian serous cyst adenocarcinoma showed alter-
ations of 39% (Figure 3E, left panel), whereas patient samples
from other cancer types also showed alterations in this 3q
gene set (Figure 3E, left panel). Analysis of the same data sets
for the 8q riboproteome gene locus identified breast invasive
carcinoma to harbor frequent alterations to genes in this locus
(21% of cases, 103 of 482 cases) (Figure 3F, left panel). Ovarian
serous cyst adenocarcinoma patients also showed significant
alteration (38%%, 121 of 316 cases), whereas prostate cancer
patients showed alteration in 13% of patients at this locus (11
of 82 cases [Figures 3F, left panel and S3E]). Accordingly, closer
analysis of 3q26 and 8q24 riboproteome gene groups in individ-
ual patients clearly demonstrates frequent coamplification of
these genes, in linewith our hypothesis that riboproteomic genes
are preferentially amplified in cancer (Figures 3E and 3F, right
panels). Similarly, the 1q22 locus demonstrates a frequent
amplification in various cancer types (Figure S3D).
Interestingly, both 3q26 and 8q24 harbor established onco-
genes PIK3CA and MYC, respectively. Although it may be con-
sidered that the riboproteomic genes in these regions may be
simply amplified along with the dominant oncogene at the rele-
vant locus, our cBio analysis clearly identifies a number of pa-
tients with invasive breast carcinoma without MYC amplification
or mutation, while still harboring amplification of 8q24 ribopro-
teome genes (Figure 3F, right panel), suggesting that they have
the potential to promote tumorigenesis independent of MYC.
We also noted that the amplified riboproteomic loci were infre-
quently coamplified in a number of cancer types. For example,
limited co-occurrence of 3q26 and 1q22 amplification is
observed in patients from lung adenocarcinoma and breast inva-
sive carcinoma cancer data sets (Figures S3F and S3G).
The Riboproteomic Platform for the Identification of
Riboproteomic Components and Regulators of
Translation
Next, we focused on differences in N/C cells as well as C/C cells
to identify riboproteomic components and as ameans to validate
our approach. As mentioned above, our data sets revealed
marked differences in proteins quantified between polysomal
fractions of normal and cancer cells (i.e., RWPE1 and PWR1E
cells compared to Du145 cells), indicating that the Du145 cancer
cells display numerous differences in the composition of their
riboproteome (Figures 1D and S1D). These differences encom-
pass a variety of protein types and include a number of potentialents utilizing prostate cell lines are shared between each of the individual data
hared by all five experiments.
eriments. Proteins identified in a single experiment (30%) are highlighted by the
) are indicated by a bold border.
different pathways and functional groups that are significantly enriched in the
entified by DAVID analysis is shown.
in (RBP) interactome identified by Castello et al. (2012) and the riboproteome
verlapwith the riboproteome. The left panel shows the percentage of identified
re riboproteomic data set (i.e., identified in all five experiments). Right panel
ata set are distributed among the various RBP-interactome categories defined
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ribosome-associated proteins that were reproducibly enriched
on the polyribosomes of either normal or cancer cells, including
intracellular adhesion molecule 1 (ICAM1), vimentin (VIM), and
Integrin b1 (ITGB1) that are enriched in cancer cells as well as
the RBPs IGF2BP2 and IGF2BP3 that were among others repro-
ducibly enriched in normal cells (Figures S4A and S4B; Tables S3
and S4). In order to further establish the relevance of the ribopro-
teome in the context of cancer, we focused on differentially
quantified proteins associated with polyribosomes of prostate
cancer cells (i.e., PC3 cells compared with Du145 cells) (Figures
1E and S4C; Table S5).
Among these differentially quantified proteins, MARCKS stood
out as it was a highly differential factor (Figures 1E and S4C) and
a major cellular substrate for protein kinase C (PKC), suggesting
that MARCKS might represent a regulator of cellular translation
and a candidate for further validation.
Importantly, MARCKS was strongly associated with polyribo-
somes of the prostate cancer cell line PC3 when compared to
Du145 cells (Figure 4A). To further confirm this observation, we
isolated polysomal fractions from three prostate cancer cell lines
(PC3, PPC1, and Du145) as well as the two normal immortalized-
epithelial control cell lines (PWR1E, RWPE1) and subjected
pooled polysomal fractions to western blot analysis. Indeed,
we were able to confirm that PC3 and PPC1 cells displayed
increased amounts of MARCKS on polyribosomes when
compared to either Du145 or prostatic epithelial cell lines (Fig-
ure 4B). In addition, these cells also displayed high levels of
phosphorylation of the PKC sensitive serine residues of
MARCKS (S159 and S163) (Figure 4B). This analysis also vali-
dated our SILAC findings that ribosomal protein levels (e.g.,
RpS6, RpS14, and RpL7a) remain unaltered between cancer
cell lines (Figure 4A). In contrast to MARCKS, our SILAC analysis
revealed that Integrin b1was highly enriched in Du145 cells when
compared to PC3 cells, andwestern blot analysis also confirmed
this differential enrichment (Figure 4A).
To extend this validation and analysis further, we carried out
additional western blot analysis on lysates from each of the pros-
tate cell lines utilized in this screening. As expected, we were
able to confirm the presence of all proteins analyzed in the poly-
somal fractions collected (Figure 4C). Additionally, these data
confirm the SILAC predictions regarding differential expression
of proteins (e.g., compare Integrin b1 in PC3 and Du145 lysates,
or IGF2BP3 in Du145 and RWPE1 lysates, Figure 4C).
As an additional validation for polysomal association, we
employed a well-established method of puromycin-mediatedFigure 3. Alterations to the Riboproteome in Cancer
(A) Forest plot highlighting the enrichment of amplifications among riboproteomi
(B) A similar forest plot demonstrating significantly less heterozygous deletions
background genes.
(C) Circos plot to illustrate the distribution of all riboproteomic components acros
their genomic localization, whereas internal red regions highlight genomic region
TCGA repository.
(D) Table detailing the top amplified genes as identified in the TCGA repository a
(E and F) Summary from the TCGA for riboproteome genes in the regions of 3q and
panels show the number of patients harboring an alteration from the data sets an
carcinoma for the 8q locus were found to show high levels of alteration in both c
(amplification, homozygous deletion, or mutation).
See also Figure S3.
Cell Redissociation of ribosome-mRNA complexes (Blobel and Saba-
tini, 1971). As shown in Figure S4E, puromycin treatment results
in the loss of RpS6 and RpL13a from polyribosomes as deter-
mined by western blot analysis of pooled polysomal fractions.
As an example of a riboproteome component associating with
polyribosomes, the presence of MARCKS was also dramatically
decreased in polyribosome fractions upon puromycin treatment
(Figures 4D and S4E), which in addition supports the hypothesis
that MARCKS plays a role in translation through association with
actively translating ribosomes.
We next hypothesized that the riboproteomic platform would
allow for the identification of mechanisms of response to
pharmacological perturbation and for translational targets that
could be differentially exploited for therapeutic intervention in
cancer.
To this end, we performed riboproteomic analysis upon inhibi-
tion of mTOR using the inhibitors rapamycin (a TORC1 inhibitor
[Thoreen and Sabatini, 2009]) and PP242 (a mTOR kinase inhib-
itor that inhibits TORC1 and TORC2 activity simultaneously
[Feldman et al., 2009]) as mentioned above. This analysis re-
vealed that the riboproteome is indeed differentially responsive
to treatment modalities. Although, we find that rapamycin has lit-
tle impact on the composition of the riboproteome (Figure S1E;
Table S6), the more potent mTOR kinase inhibitor PP242 results
in a much stronger and more robust perturbation of the ribopro-
teome (Figure 1F; Table S7). Indeed, although inhibition of mTOR
by PP242 identifies a number of proteins, including some ribo-
somal proteins (e.g., see RpL4, RpL6, and RpS6 in Figure S4D;
Table S7) that show a rapid and significant disassociation from
the riboproteome upon treatment with PP242, this may repre-
sent a more general dissociation of the ribosome and a block
in translation. Interestingly, the RBP LARP1 (La ribonucleopro-
tein domain family member 1) appeared to be one of the most
dynamic components of the riboproteome in response to
mTOR inhibition by PP242 (Figures 1F and 4E). Although the
function of LARP1 is not completely understood, it has been re-
ported to play a role in cell division, apoptosis, and migration
(Burrows et al., 2010), and it has been shown to be an mTOR-
sensitive phosphoprotein (Hsu et al., 2011; Yu et al., 2011). We
confirmed the RNA binding activity of LARP1 (Burrows et al.,
2010), by using a micrococcal nuclease (MN) assay (Darnell
et al., 2011). Pooled sucrose gradient fractions containing
LARP1 protein were treated with and without MN. Ribosomes
were subsequently pelleted by ultracentrifugation, and the
protein in supernatant and pellet were isolated for western blotc genes when compared to background genes in the cBio TCGA data set.
among riboproteomic genes in the cBio TCGA data set when compared to
s the genome. Blue bars represent individual riboproteomic components, and
s containing riboproteome genes found to be most frequently amplified in the
nd organized according to genomic loci.
8q, respectively, that are found to be frequently amplified in human cancer. Left
alyzed. As lung squamous cell carcinoma for the 3q locus and breast invasive
ases, the right panels illustrate the types of alteration found in these patients
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Figure 4. Riboproteomics Uncovers Ribo-
some-Associated Proteins
(A) Western blot analysis of total lysates and pol-
ysomal fractions from PC3 and Du145 H- and L-
labeled cell lines. Western blots for MARCKS,
RpL7a, Integrin b1, RpS6, RpS14, and b-actin are
shown.
(B) Western blot analysis of pooled polysomal frac-
tions showing differential enrichment of phospho-
MARCKS and MARCKS from ribosomes of Du145,
PC3, PWR1E, and RWPE1 cells (right panel) and
PC3, PPC1, Du145, and PWR1E cells (left panel).
Ponceau S staining served as a loading control.
(C) Western blot analysis from pooled polysomal
fractions validating ribosome-associated proteins
from ribosomes of PC3, PPC1, Du145, RWPE1
and PWR1E cells. For this analysis, polyribosomes
have been isolated from all cell lines and fractions
have been pooled to obtain subunits (S, fractions
#3-5, see Figure S1A), early light polysomes (L,
fractions #6-8, see Figure S1A) and late heavy
polysomes (H, fractions #9-11, see Figure S1A).
Western blots for Integrin b1, IGF2BP3, hnRNPC1/
2,Calmodulin, Hsp27, Hsp60 andNPMare shown.
Ponceau S staining served as a loading control.
(D) PC3 prostate cancer cells were subjected to
puromycin-mediated dissociation of ribosome-
mRNA complexes to demonstrate a specific as-
sociation of MARCKS with the ribosome. Protein
was isolated from individual fractions (#1–#7) of
the sucrose gradients using TCA/DOC precipita-
tion and subjected to western blot analysis for
MARCKS. The relative distribution of MARCKS
across the sucrose gradient was quantified using
the ImageJ software (http://rsbweb.nih.gov/ij).
(E)Western blot analysis fromprotein isolated from
individual fractions across the sucrose gradients of
PPC1 cell lysates treated with DMSO or PP242.
Shift in LARP1 (upper left panels) and RpL4 (lower
left panels) proteins can be readily observed upon
treatment with the mTOR kinase inhibitor. Right
panel: rate of change between DMSO and PP242
conditions for LARP1 (green) and RpL4 (blue) from
late to early fractions (#9–#3).
See also Figure S4.analysis. As seen in Figure S4F, LARP1 behaved similar to the
well-characterized poly-A binding protein (PABP). Without MN
treatment, LARP1 pelleted with ribosomal proteins, indicating
its close association with polysome components. However,
upon treatment with MN, LARP1 no longer associated with ribo-
proteome components and is released into the supernatant
similar to PABP (Figure S4F). This indicates that LARP1 is pre-
dominantly an RBP, showing limited association with the ribo-
some itself. In addition, treating cells with PP242 prior to this
analysis, we observed that, whereas PABP appears to remain
tightly intact with polysome fractions, there appears to be
more LARP1 observed in the supernatant, suggesting that
mTOR inhibition can selectively influence binding of LARP1 at
the polysome (Figure S4G). Thus, these findings suggest that
mTOR activity toward LARP1 may represent an additional
means by which mTOR can regulate translation.
Finally, to examine whether the riboproteome is altered in
response to a genetic perturbation, we carried out SILAC ribo-1284 Cell Reports 4, 1276–1287, September 26, 2013 ª2013 The Auproteomic analysis on Npm1 wild-type and null immortalized
MEF (immortalized by deletion of the Trp53 gene) (Figure S1F).
Again, SILAC analysis of polysome fractions demonstrated a
high similarity between riboproteome components, with ribo-
somal proteins themselves showing no quantitative difference
between the Npm1 wild-type or null MEF preparations (Fig-
ure S1F; Table S8). However, there were a number of proteins
that demonstrated differential association with polysomes from
Npm1 wild-type and null MEFs, which may be relevant for trans-
lation in these cells (Figures S1F and S4H). Interestingly, we iden-
tified the heterogeneous nuclear ribonucleoprotein hnRNPC to
be one of the most highly increased proteins on the polysomes
of Npm1-null MEFs (Figure S4I; Table S8).
Thus, taken together these data validate this approach as an
effective means to study riboproteome composition in a wide
variety of cellular contexts and highlight this approach as a valu-
able resource that can be applied to the study of how perturba-
tions to genes and pathways impact the riboproteome.thors
DISCUSSION
Over the last number of years, there has been increasing aware-
ness of the role that ribosome, ribosome biogenesis, and various
other factors that relate to translation play in normal cellular
homeostasis, and in human disease (Xue and Barna, 2012).
However, there is a pressing need to understand in greater detail
the many factors that contribute to ribosome function and the
regulation of translation on a global scale. Thus, we set out to
analyze in a nonbiased, high-throughput manner the numerous
factors that coordinate ribosome function andmRNA translation.
Here, we present an overview of the riboproteome, as character-
ized by analysis of several different cell lines and different cellular
contexts.
The general overview described here allowed us to draw a
number of important conclusions relating to the various elements
that make up the riboproteome and allowed us to gain new
insight into how the ribosome and translation is regulated.
First, by cross-referencing data from independent SILAC ribo-
proteomic experiments, and using a comprehensive panel of
prostate cell lines, we were able to identify a core group of pro-
teins that are consistently identified in all experimental data sets,
whereby at least 70% of proteins quantified were found in at
least two experimental data sets. From this global analysis, we
show that our data set is highly enriched in factors that relate
directly to the ribosome, to translational initiation and elongation,
and to pathways that are known to regulate and control transla-
tion. Importantly, this comprehensive analysis also reveals that
the riboproteome consists of significant proportion of RBPs.
As recently reported, the mRNA-interactome revealed that a
wide variety of proteins previously unappreciated as RBPs can
bind tomRNA (Castello et al., 2012; Baltz et al., 2012). This diver-
sity of RBP functionality is also observed in those RBPs repre-
sented in our data set. However, there is also a large proportion
of proteins that we identify, even as core riboproteome compo-
nents, that are not annotated as having RNA binding properties,
indicating a further layer of functional complexity in those pro-
teins that work to regulate ribosome function and translation.
Second, our data sets indicate that the diversity within the
riboproteome itself may have the capacity to categorize cell
types and tissues and, importantly, may specifically contribute
to regulation of gene expression within a given cellular compart-
ment. Surprisingly, in the data sets we have analyzed the plas-
ticity of the riboproteome does not appear to extend to individual
ribosomal proteins themselves that are evenly represented in the
various cell types investigated, and they appear to be uniformly
altered in response to conditions that impact ribosomal transla-
tion, such as mTOR inhibition.
Third, by examining globally how the riboproteome may be
altered in diseases such as human cancer, we havemade further
unexpected observations. We find that riboproteomic compo-
nents display frequent copy-number amplifications in human
cancer, whereas genomic losses within the riboproteome are
significantly less than that for nonriboproteomic genes. We
further identified three genomic loci around 3q26, 8q24, and
1q22 containing genes that appear to be altered in a significant
number of patients for several of the cancer subtypes contained
in the cBio TCGA database. It is worth noting that both the re-Cell Regions 3q26 and 8q24 contain the oncogenes PIK3CA and
MYC, respectively. Although MYC and PIK3CA are frequently
amplified in cancer (Beroukhim et al., 2010; Brown et al., 2012;
Kolasa et al., 2009), there are several examples within the cBio
data sets that the riboproteomic genes within these regions
may be amplified without coamplification of the resident onco-
gene. It is also interesting to note that both MYC and the PI3-
kinase signaling pathway represent important regulators of
translation themselves.
Fourth, in addition to characterizing the riboproteome
landscape in various cell types, we identified and validated a
number of proteins previously not known to be associated with
actively translating ribosomes (e.g., MARCKS, Integrin b1, and
IGF2BP3). These proteins represent a number of interesting
ribosome interactors and highlight the diversity of proteins that
actually participate in translation. In addition, they also point to
the potential of these data sets to identify novel regulators of
translation. Definitive riboproteome categorization of each pro-
tein identified will require validation as has been carried out for
proteins in this study, to fully endorse them as bona fide compo-
nents of the riboproteome. Although given the high enrichment
for RBPs, elongation/initiation factors, and known ribosome
biogenesis proteins, it is likely that many of these unexpected
proteins are true riboproteome components.
Last, our data demonstrate that the cancer riboproteome can
be pharmacologically modulated for therapy on the basis of this
molecular knowledge. On the one hand, we show that the ribo-
proteome responds dynamically and differentially to cancer
drugs (e.g., rapamycin versus PP242), whereas, on the other
hand its differential composition could be used to tailor therapies
and predict outcomes based on the riboproteomic profile of spe-
cific cell types.
Thus, quantitative, high-throughput riboproteomics repre-
sents a powerful platform that can be readily applied to various
cellular models to uncover how riboproteome composition con-
tributes to organismal function and disease.
EXPERIMENTAL PROCEDURES
SILAC Labeling and Mass Spectrometry
Metabolic labeling of prostate cell lines (PC3, PPC1, Du145, RWPE1, and
PWR1E) and MEFs was carried out using either normal arginine and lysine
or heavier isotopic variants of the two amino acids (L-lysine 2HCL [U-13C6],
L-arginine HCL [U-13C6, U-N15N4]) (Ong et al., 2002) using Invitrogen’s
SILAC-FLEX Media kits. SILAC-labeled protein mixtures were run by
SDS-PAGE, and gel lanes were cut into eight sections for overnight digestion
at pH 8.0 with modified sequencing grade trypsin (Promega). Peptidemixtures
were eluted, and each gel section was analyzed separately by microcapillary
LC-MS/MS using the EASY-nLC nanoflow HPLC (Thermo Fisher Scientific)
with a 75 mm inner diameter 3 15 cm length Picofrit capillary column (New
Objective) self-packed with 5 mm Magic C18 resin (Michrom Bioresources)
coupled to a hybrid LTQ Orbitrap XL-ETD mass spectrometer (Thermo Fisher
Scientific). The LTQ Orbitrap XL was operated in data-dependent acquisition
Top 5 mode (1 profile FT-MS spectrum followed by six centroided IT-
MS/MS spectra). The resolution was 30,000 in FT-MS mode and MS/MS
spectra were read out at low resolution in the LTQ XL ion trap. The gradient
consisted of 3%–38% acetonitrile in 0.1% formic acid (FA) at a flow rate
of 300 nl/min for 75 min, 38%–95% acetonitrile in 0.1% FA for 2 min and
held at 95% acetonitrile in 0.1%FA at for 7min followed by column reequilibra-
tion for 10 min at 3% acetonitrile in 0.1% FA. MS/MS fragmentation spectra
were searched for protein identification using the Andromeda search engineports 4, 1276–1287, September 26, 2013 ª2013 The Authors 1285
(http://www.andromeda-search.org) (Cox et al., 2011) against the reversed
and concatenated IPI_HUMAN protein database (v3.87) (http://www.ebi.ac.
uk/IPI/IPIhuman.html). Carbamidomethylation of cysteine was set as fixed
modification and variable modifications were oxidation of methionine and pro-
tein N-acetylation. Raw files for SILAC ratio analysis from each experiment
were combined and processed using MaxQuant v1.2.2.5 software (http://
www.maxquant.org/) (Cox and Mann, 2008). Initial peptide mass tolerance
was set to 12 ppm, and fragment ion mass tolerance was set to 0.8 Da. Two
missed cleavages were allowed and the minimal length required for a peptide
was six amino acids. One unique peptide was required for high-confidence
protein identifications and a minimum ratio count of two peptides (one unique
and one razor) were required for SILAC ratio determination. The peptide and
protein false discovery rates (FDR) were set to 0.01. Normalized SILAC ratios
(H/L) were used for subsequent analysis.
Polysome Isolation and Analysis
Polysome profiles were prepared fromMEFs and different prostate cancer cell
lines as follows. MEFs were seeded at 2 3 106 cells/15 cm and PPC1, PC3,
Du145, RWPE1, and PWR1E cells seeded at 10 3 106 cells/15 cm dish and
cultured overnight to ensure subconfluent cultures for polysome analysis.
PPC1 cells were treated the following day with either DMSO, rapamycin
(20 nM) or PP242 (500 nM) for 3 hr. For polysome preparation, cells were
then incubated with cycloheximide at a final concentration of 100 mg/ml for a
period of 15 min. Plates were then washed with ice-cold PBS containing
100 mg/ml cycloheximide (PBS/CHX), scraped, and collected in ice-cold
PBS/CHX. Cells were pelleted by centrifugation and subsequently lysed in
polysome lysis buffer (20 mM Tris-HCl [pH 7.4]; 5 mM MgCl2; 150 mM NaCl;
1% Triton X-100; 1% deoxycholate; 2.5 mM DTT; 200 U/ml RNasin;
100 mg/ml cycloheximide; 13 complete, EDTA-free protease inhibitor cocktail
[Roche]; 1 3 protease inhibitor set [without EDTA] [G-Biosciences]; a1-anti-
trypsin [EMD Biosciences]) and incubated on ice for 10 min with occasional
mixing. Extensive optimization of cell lysis was carried out to identify suitable
lysis buffer conditions that completely blocked protein degradation from
endogenous proteases, and we found it necessary to include the extensive
array of protease inhibitors provided in the G-Biosciences protease inhibitor
set. Lysates were centrifuged at 7,000 rpm for 5 min at 4C, and the superna-
tant carefully removed. Protein concentrations for lysates were measured by
Bradford assay, and equal amounts of protein loaded on a 15%–50% sucrose
gradient containing 100 mg/ml cycloheximide, 0.2 mg/ml heparin, and 1 mM
DTT. Gradients were centrifuged at 36,000 rpm for 3 hr at 4C in a Beckman
SW40 rotor and subsequently fractionated using an ISCO-Foxy Jr. fraction
collector. Polysome profiles were reordered using a UA-6 absorbance detec-
tor connected to the fraction collector and measuring absorbance at 254 nm.
Puromycin-induced polysome dissociation was carried out by the addition
of 1 mM puromycin directly to the lysis buffer lacking cycloheximide as previ-
ously described (Blobel and Sabatini, 1971; Fuchs et al., 2011). Briefly,
following lysis, the samples were incubated at 37C for 15 min to dissociate
ribosome-mRNA complexes. Lysates were centrifuged at 13,000 rpm for
5 min at 4C, and the supernatant was carefully removed and loaded on a
15%–50% sucrose gradient. Gradients were centrifuged and fractionated as
described above.
Bioinformatics Analysis of the Riboproteome
To cluster riboproteome experiments based on the riboproteins identified in
each experiment, we created a Booleanmatrix of riboproteome genes by ribo-
proteome experiments, in which each entry in the matrix was a 1 if the row’s
gene was identified in the column’s experiment, and a 0 otherwise. Clustering
of the experiments was then performed using a binary distance measure to
compute the distance matrix and average linkage for hierarchical clustering,
implemented with the R functions dist and hclust.
Venn diagrams indicating membership of riboproteome genes to SILAC
experiments were created using the Vennerable package in R.
To identify functional gene sets enriched in the riboproteome genes, we
uploaded the riboproteome genes to Ingenuity Pathway Analysis (http://
www.ingenuity.com) and identified the top biological functions gene sets
and canonical pathways gene sets enriched in the riboproteome gene set.
To identify KEGGpathways specifically enriched in the subset of riboproteome1286 Cell Reports 4, 1276–1287, September 26, 2013 ª2013 The Augenes identified in five of five experiments as compared with the set identified
in only one of five experiments, we uploaded the five of five experiments gene
list to DAVID and used the one of five experiments gene list as background.
Gene ontology analysis was carried out using the online DAVID bioinformat-
ics resource tool.
TCGA-Based Analyses of RiboproteomeGenomic Alterations across
Human Cancers
To analyze global patterns of copy-number alterations in the riboproteome
versus the background protein-coding genome, we used the cgdsr package
in R to download Gistic copy-number alteration calls from the 16 cancer types
with available data for a large portion of the riboproteome (between 1,661 and
1,720 of the riboproteome genes analyzed for each cancer type, median =
1,675) and the background protein coding genome (19,195 genes). For each
cancer type, we recorded the number of homozygous deletions (GISTIC
score = 2), hemizygous deletions (GISTIC score = 1), diploid (GISTIC
score = 0), low-level copy-number gain (GISTIC score = 1), and high-level
amplification (GISTIC score = 2) among the riboproteome genes and among
the background genome. We compared the proportion of each of the GISTIC
scores observed among the riboproteome genes to the proportion observed
among the background protein-coding genome using the function prop.test
in R. To visualize and summarize the distribution of the proportions of alter-
ations across the cancer types, we created forest plots using the rmeta
package.
After characterizing the global properties of riboproteome genomic alter-
ations in human cancers, we performed gene-level analyses. At the time of
analysis, the cBio Cancer Genomics Portal contained five published data
sets and 15 provisional data sets from The Cancer Genome Atlas (TCGA)
profiling efforts (Cerami et al., 2012). Although the five published data sets
contain mutation data, the provisional TCGA data sets do not.
These analyses were limited to the 532 riboproteome genes with valid data
across 15 TCGA cancer types. For each gene, we computed the proportion of
cases of each cancer type that the gene showed homozygous deletion, hemi-
zygous deletion, diploid, low-level amplification, and high-level amplification,
based on GISTIC calls downloaded via cgdsr. For each riboproteome gene,
we computed its maximum proportion of each type of alteration across the
TCGA cancer types. Riboproteome genes and locations of riboproteome
genes undergoing frequent amplifications in cancer were visualized with Cir-
cos-like plots, implemented using ggplot in R.
Western Blot Analysis
Cells were lysed in lysis buffer containing Complete Mini protease inhibitors
(EDTA free) (Roche) and a Phosphatase Inhibitor cocktail (Thermo Scientific).
Total protein (5–50 mg) was subjected to SDS-PAGE on 4%–12% Bis-Tris
acrylamide NuPAGE gels in MOPS SDS running buffer (Invitrogen). The
following primary antibodies were used: MARCKS, phospho-MARCKS
(S152/156), Integrin b1, Calmodulin, Hsp27, Hsp60, RpL13a, RpL7a, and
RpS6 (all Cell Signaling Technology), HSP90 (BD Biosciences; BD Transduc-
tion Laboratories), hnRNPC1/C2 (Millipore), and Rps14 and b-actin (all from
Santa Cruz Biotechnologies). The NPM1 antibody was from DAKO and the
IGF2BP3 antibody was from ProteinTech. Subsequently, membranes were
incubated with secondary HRP-tagged antibodies (Amersham), and signals
were visualized with ECL or ECL plus (Amersham). It is important to note
that we used Ponceau S staining as a control for equal protein loading in our
western analysis of polysomal fractions, because typical housekeeping genes
like b-actin or a-tubulin are not enriched in riboproteome preparations and
therefore only barely detectable in polysome fractions (Figure 4A; data not
shown).
For further details on the materials and methods used in this study, please
see the Extended Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, four
figures, and nine tables and can be found with this article online at http://dx.
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